Kenai Therapeutics has finished enrolling patients in its REPLACE trial, testing RNDP-001 — an off-the-shelf cell therapy aimed at restoring dopamine-producing neurons destroyed by Parkinson's disease. The therapy uses induced pluripotent stem cells to potentially replace what the brain loses as the disease progresses. The Phase 1b/2a trial is evaluating safety, tolerability, and early signs of effectiveness across multiple clinical sites. Backed by FDA Fast Track designation and California regenerative medicine funding, this represents a meaningful step toward a restorative — rather than merely symptomatic — treatment for one of the most debilitating neurodegenerative diseases affecting older adults. Initial safety and efficacy data are expected to follow.
